Beatriz Suarez-Romero

Beatriz Suarez-Romero

Auto-generated profile, based on publicly available information

Beatriz Suarez-Romero

Departamento de Medicina general, Corporación Rafael Núñez, Cartagena-Colombia

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2022 in Revista de la Sociedad Ecuatoriana de Nefrología, Diálisis y Trasplante
Verified
Journal Article
Open access
PDF file
Jorge Rico FontalvoJorge Rico Fontalvo
Jorge Rico Fontalvo
RDRodrigo Daza-Arnedo
Rodrigo Daza-Arnedo
TYTomas Rodriguez Yanez
Tomas Rodriguez Yanez
WOWashington Osorio
Washington Osorio
BSBeatriz Suarez-Romero
Beatriz Suarez-Romero
JGJuan Camilo Gutierrez
Juan Camilo Gutierrez
Introduction: Chronic kidney disease associated with obesity (CKD-WO) has increased in prevalence in recent decades. It is characterized by excess adipocytic hormonal imbalances (adipokines), deregulation of the energy balance system, and imbalances in metabolic homeostasis. Purpose of the review: The objective is to outline the different pathophysiological mechanisms' role in developing functional or anatomical kidney disease in obese patients. We look for updated reports that include the best survival results for patients with CKD. Recent findings: We currently know that CKD-WO has a chronic pro-inflammatory behavior. Obesity and overweight are associated with hemodynamic, structural, and histopathological alterations in the kidney and metabolic and biochemical alterations that predispose to kidney disease, even when renal function and conventional tests are normal. Conclusions: We classify CKD-WO in Type 1: Obesity and potentially reversible functional alterations. Type 2: Obesity and potentially non-reversible histopathological structural alterations (includes glomerulopathy associated with obesity and focal segmental glomerulosclerosis). Type 3: Obesity-related to chronic diseases (diabetes, hypertension, pulmonary hypertension, heart failure). Type 4: Obesity in the patient with renal function replacement therapy.